A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation

Autor: B. López, J. Nieto, J.A. Hernández-Plata, A.L. González-Jorge, J.M. Alcántar-Fierros, P. Castañeda, G. Varela-Fascinetto, M.A. Flores-Hernández, J.L. Sánchez, D.P. Soriano-López, P. Valencia-Mayoral, S. Velázquez-Ramos, V. Fuentes
Rok vydání: 2016
Předmět:
Graft Rejection
Male
medicine.medical_specialty
Epstein-Barr Virus Infections
Herpesvirus 4
Human
Lymphoma
medicine.medical_treatment
Lymphoproliferative disorders
030230 surgery
Liver transplantation
Opportunistic Infections
Single Center
Gastroenterology
Polymerase Chain Reaction
03 medical and health sciences
0302 clinical medicine
Postoperative Complications
hemic and lymphatic diseases
Internal medicine
medicine
Humans
Child
Epstein–Barr virus infection
Retrospective Studies
Immunosuppression Therapy
Transplantation
business.industry
Incidence (epidemiology)
Immunosuppression
Retrospective cohort study
Viral Load
medicine.disease
Lymphoproliferative Disorders
Liver Transplantation
surgical procedures
operative
Early Diagnosis
Child
Preschool
Immunology
030211 gastroenterology & hepatology
Surgery
Female
business
Viral load
Zdroj: Transplantation proceedings. 48(2)
ISSN: 1873-2623
Popis: This is a cohort, retrospective, comparative study of all liver transplant recipients from a single center, from May 1998 to July 2015. Patients were divided into two groups according to the type of Epstein-Barr viral load monitoring. For group I (1998-2007), polymerase chain reaction (PCR) was not available or it was only qualitative with limited access. For group II (2008-2015), we used periodically scheduled quantitative PCR in plasma and leukocytes, with aggressive tapering of immunosuppression as soon as viral replication was detected. Ninety-eight recipients were included, 41 (41.8%) were Epstein-Barr virus (EBV) - seronegative before liver transplantation (LT). EBV replication was confirmed in 74 patients (75.5%), being more frequent in seronegative (87.8%) than seropositive patients (66.6%). Eight recipients (8.1%) developed post-transplantation lymphoproliferative disorder (PTLD) on average at 14.3 months post-LT, seven of eight were
Databáze: OpenAIRE
Externí odkaz: